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KLF4 decreases leukemia cell 
proliferation by regulating transcription 
of multiple gene targets. KLF2 and 
KLF4 expression slows the proliferation 
rate in both (A) CML and (B) AML cell 
lines, and is not reversed by miR-150 
inhibition. (C) KLF4 expression reduces 
MYC expression, alters expression of 
MYC targets associated with 
metabolism, and stimulates MXD1 
transcription, a combination that is 
known to limit proliferation. (D) 
Schematic of a gene network regulated 
by KLF4 to limit proliferation and 
promote differentiation. 
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In acute myeloid leukemia (AML) myeloid progenitor/stem cells fail to differentiate and instead 
remain in an immature and hyper-proliferative state. Traditional therapies used to treat AML and 
other types of cancer have been cytotoxic agents that induce cell death or apoptosis. As our 
understanding of these malignancies grows new therapeutic approaches become viable. In the case 
of AML, researchers are also exploring the possibility of differentiation therapy. In this approach 
leukemic cells are forced to differentiate into a more mature cell type, essentially converting the 
proliferating leukemia cells into a benign cell with a limited life span. Central to the differentiation 
process are transcription factors, which have been well studied in AML. Of recent interest has been 
the family of Krüppel-like factors (KLF). In normal hematopoiesis KLF2 and KLF4 drive myeloid cell 
differentiation and limit proliferation by increasing expression of the tumor suppressor and cyclin-
dependent kinase inhibitor p21. Moreover, it was recently shown in a small number of AML patient 
samples that KLF4 expression is silenced. In a study from the Oehler Laboratory (Clinical Research 
Division) published in Molecular and Cellular Biology, researchers elucidated a network of microRNA 
and proteins downstream of KLF4 that regulate proliferation and differentiation in AML cells.  
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First, the scientists confirmed that KLF4 expression is commonly decreased in AML cells using 
publicly available microarray data sets of AML patient samples. KLF4 expression was significantly 
reduced in most AML samples compared to CD34
+
 hematopoietic progenitors from healthy patients, 
though patient-to-patient heterogeneity was common. Researchers further verified that KLF4 and to 
a lesser extent KLF2 expression induced differentiation and reduced proliferation of the AML patient 
derived cell line THP-1. Surprisingly, gene expression changes in KLF4 transduced cells were 
similar to changes observed when cells are transduced with the microRNA, miR-150. Decreased 
expression of miR-150 has also been commonly observed in AML and re-expression of this miRNA 
in a murine leukemia model inhibited cancer cell growth. These findings led researchers to explore if 
expression of miR-150 is regulated by KLF4. The first step was to identify the promoter region of 
miR-150 and then to predict transcription factor binding sites, which among a dozen sites included 
two GC-rich elements that commonly bind KLF transcription factors. Using the miR-150 promoter to 
drive luciferase expression it was shown that KLF2 and KLF4 increased luciferase production, and 
mutation to either of the GC-rich elements prevented this activity. Thus KLF4 and KLF2 positively 
regulate miR-150 transcription. 
The initial hypothesis from these results was that KLF4-mediated differentiation in AML was the 
result of miR-150 expression. However, genomic knock out of miR-150 with CRISPR/Cas9 did not 
prevent KLF4-mediated differentiation. KLF4 also activates the tumor suppressor p21 (also called 
CDKN1A), so researchers performed a double knockout of miR-150 and CDKN1A in KLF4 
expressing cells. The double knockout also failed to prevent differentiation, suggesting KLF4’s 
effects on differentiation are the result of other uncharacterized downstream regulators. To identify 
these unknown KLF4 targets microarray expression profiles were determined for KLF4 positive cells 
expressing three unique CRISPR sgRNA: non-targeting control, miR-150, and CDKN1A. From these 
gene expression profiles, researchers identified alterations that were common to all three conditions, 
as each condition is anti-proliferative and differentiates. Numerous cytokines and transcription 
regulators were included in the group, such as TNF, NFkB, and E2F2; however, of most interest was 
the inverse relationship between MYC and MXD1. Elevated KLF4 levels repressed MYC and 
activated MXD1 expression. These two related transcription factors have opposing effects on cells: 
MYC activates proliferation and metabolism, while MXD1 promotes cell cycle arrest. KLF4 
expression also decreased BTK levels, which is overexpressed in AML and also contributes to MYC 
activation. This network of KLF4 regulated proteins can now be further dissected to understand how 
they contribute to differentiation and cell cycle arrest. Moreover, targeting genes in this network 
could be exploited as a therapeutic strategy. While this research focused on AML, Dr. Valerie Morris 
(Clinical Research Division) commented that such a therapy may apply to other cancers as well, 
"KLF4 has been described as a tumor suppressor regulating proliferation, apoptosis and 
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differentiation in other blood cancers, including both T-cell acute lymphoblastic leukemia and B-cell 
lymphomas, as well as various solid tumors, including colon and lung cancer." Such a therapy could 
be even further reaching and benefit any cancer with low KLF4 levels, "KLF4 expression is low or 
absent in a number of other malignancies including various gastrointestinal malignancies, brain 
tumors and lung cancer." Said Dr. Vivian Oehler (Clinical Research Division). 
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